prior to now several years, the UK has witnessed a revolution in clinical bodyweight‑reduction therapies — from the introduction of semaglutide (Wegovy®) on the expanding acceptance of tirzepatide (Mounjaro®). Now, another title is drawing focus in equally clinical and general public wellness cir